# Altimmune, Inc.: financial statements, quarterly

ALT · Nasdaq · CIK 1326190 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/alt.md) · [Financials](/companies/alt/financials.md) · [Filings](/companies/alt/filings.md) · [Insiders](/companies/alt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/alt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.4](/filings/0001326190-24-000050.md) | [0.0 d](/filings/0001326190-25-000015.md) | [0.0](/filings/0001326190-25-000034.md) | [0.0](/filings/0001326190-25-000040.md) | [0.0](/filings/0001326190-25-000064.md) | [0.0 d](/filings/0001326190-26-000018.md) | [0.0](/filings/0001326190-26-000040.md) | [0.0](/filings/0001326190-26-000052.md) | [0.0](/filings/0001326190-25-000064.md) | [0.0 d](/filings/0001326190-26-000018.md) | not reported | not reported |
| Research and development | $m | [18.4](/filings/0001326190-24-000050.md) | [16.9 d](/filings/0001326190-25-000015.md) | [21.5](/filings/0001326190-25-000034.md) | [21.2](/filings/0001326190-25-000040.md) | [19.8](/filings/0001326190-25-000064.md) | [19.8 d](/filings/0001326190-26-000018.md) | [15.8](/filings/0001326190-26-000040.md) | [17.2](/filings/0001326190-26-000052.md) | [15.0](/filings/0001326190-25-000064.md) | [18.4 d](/filings/0001326190-26-000018.md) | [16.2](/filings/0001326190-26-000040.md) | [18.7](/filings/0001326190-26-000052.md) |
| Operating income | $m | [(22.5)](/filings/0001326190-24-000050.md) | [(33.6) d](/filings/0001326190-25-000015.md) | [(26.8)](/filings/0001326190-25-000034.md) | [(26.7)](/filings/0001326190-25-000040.md) | [(24.8)](/filings/0001326190-25-000064.md) | [(24.9) d](/filings/0001326190-26-000018.md) | [(21.8)](/filings/0001326190-26-000040.md) | [(22.9)](/filings/0001326190-26-000052.md) | [(20.9)](/filings/0001326190-25-000064.md) | [(28.9) d](/filings/0001326190-26-000018.md) | [(24.2)](/filings/0001326190-26-000040.md) | [(26.2)](/filings/0001326190-26-000052.md) |
| Interest expense | $m | [0.0](/filings/0001326190-23-000047.md) | [0.0 d](/filings/0001326190-24-000010.md) | [0.0](/filings/0001326190-24-000019.md) | [0.0](/filings/0001326190-25-000040.md) | [0.0](/filings/0001326190-25-000064.md) | [0.0 d](/filings/0001326190-26-000018.md) | [0.0](/filings/0001326190-26-000040.md) | [0.3](/filings/0001326190-26-000052.md) | [0.5](/filings/0001326190-25-000064.md) | [0.9 d](/filings/0001326190-26-000018.md) | [1.1](/filings/0001326190-26-000040.md) | [1.1](/filings/0001326190-26-000052.md) |
| Income tax | $m | [0.0](/filings/0001326190-24-000050.md) | not reported | [0.0](/filings/0001326190-24-000019.md) | [0.0](/filings/0001326190-24-000030.md) | [0.0](/filings/0001326190-24-000050.md) | not reported | [(0.7)](/filings/0001326190-26-000040.md) | [0.0 d](/filings/0001326190-26-000052.md) | [0.0 d](/filings/0001326190-25-000064.md) | [0.0 d](/filings/0001326190-26-000018.md) | not reported | not reported |
| Net income | $m | [(20.7)](/filings/0001326190-24-000050.md) | [(31.6) d](/filings/0001326190-25-000015.md) | [(24.4)](/filings/0001326190-25-000064.md) | [(24.6)](/filings/0001326190-25-000064.md) | [(22.8)](/filings/0001326190-25-000064.md) | [(23.2) d](/filings/0001326190-26-000018.md) | [(19.6)](/filings/0001326190-26-000052.md) | [(22.1)](/filings/0001326190-26-000052.md) | [(19.0)](/filings/0001326190-25-000064.md) | [(27.4) d](/filings/0001326190-26-000018.md) | [(22.6)](/filings/0001326190-26-000052.md) | [(22.8)](/filings/0001326190-26-000052.md) |
| Diluted EPS | $ per share | [(0.39)](/filings/0001326190-24-000050.md) | not reported | [(0.34)](/filings/0001326190-25-000034.md) | [(0.35)](/filings/0001326190-25-000040.md) | [(0.32)](/filings/0001326190-25-000064.md) | not reported | [(0.26)](/filings/0001326190-26-000040.md) | [(0.27)](/filings/0001326190-26-000052.md) | [(0.21)](/filings/0001326190-25-000064.md) | not reported | [(0.18)](/filings/0001326190-26-000040.md) | [(0.12)](/filings/0001326190-26-000052.md) |
| Basic EPS | $ per share | [(0.39)](/filings/0001326190-24-000050.md) | not reported | [(0.34)](/filings/0001326190-25-000034.md) | [(0.35)](/filings/0001326190-25-000040.md) | [(0.32)](/filings/0001326190-25-000064.md) | not reported | [(0.26)](/filings/0001326190-26-000040.md) | [(0.27)](/filings/0001326190-26-000052.md) | [(0.21)](/filings/0001326190-25-000064.md) | not reported | [(0.18)](/filings/0001326190-26-000040.md) | [(0.12)](/filings/0001326190-26-000052.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [86.9](/filings/0001326190-23-000047.md) | [135](/filings/0001326190-25-000015.md) | [79.0](/filings/0001326190-24-000019.md) | [57.1](/filings/0001326190-24-000030.md) | [31.5](/filings/0001326190-24-000050.md) | [36.9](/filings/0001326190-26-000018.md) | [49.1](/filings/0001326190-25-000034.md) | [183](/filings/0001326190-25-000040.md) | [61.2](/filings/0001326190-25-000064.md) | [43.8](/filings/0001326190-26-000052.md) | [97.6](/filings/0001326190-26-000040.md) | [63.0](/filings/0001326190-26-000052.md) |
| Current assets | $m | [153](/filings/0001326190-23-000047.md) | [210](/filings/0001326190-25-000015.md) | [188](/filings/0001326190-24-000019.md) | [171](/filings/0001326190-24-000030.md) | [146](/filings/0001326190-24-000050.md) | [137](/filings/0001326190-26-000018.md) | [155](/filings/0001326190-25-000034.md) | [188](/filings/0001326190-25-000040.md) | [217](/filings/0001326190-25-000064.md) | [278](/filings/0001326190-26-000052.md) | [335](/filings/0001326190-26-000040.md) | [335](/filings/0001326190-26-000052.md) |
| Total assets | $m | [167](/filings/0001326190-23-000047.md) | [211](/filings/0001326190-25-000015.md) | [188](/filings/0001326190-24-000019.md) | [173](/filings/0001326190-24-000030.md) | [148](/filings/0001326190-24-000050.md) | [139](/filings/0001326190-26-000018.md) | [157](/filings/0001326190-25-000034.md) | [190](/filings/0001326190-25-000040.md) | [218](/filings/0001326190-25-000064.md) | [280](/filings/0001326190-26-000052.md) | [336](/filings/0001326190-26-000040.md) | [527](/filings/0001326190-26-000052.md) |
| Current liabilities | $m | [11.9](/filings/0001326190-23-000047.md) | [12.1](/filings/0001326190-25-000015.md) | [11.3](/filings/0001326190-24-000019.md) | [15.2](/filings/0001326190-24-000030.md) | [8.6](/filings/0001326190-24-000050.md) | [10.5](/filings/0001326190-26-000018.md) | [9.8](/filings/0001326190-25-000034.md) | [9.2](/filings/0001326190-25-000040.md) | [12.6](/filings/0001326190-25-000064.md) | [15.0](/filings/0001326190-26-000052.md) | [11.3](/filings/0001326190-26-000040.md) | [12.5](/filings/0001326190-26-000052.md) |
| Total liabilities | $m | [16.2](/filings/0001326190-23-000047.md) | [16.5](/filings/0001326190-25-000015.md) | [15.4](/filings/0001326190-24-000019.md) | [20.8](/filings/0001326190-24-000030.md) | [14.5](/filings/0001326190-24-000050.md) | [15.8](/filings/0001326190-26-000018.md) | [15.1](/filings/0001326190-25-000034.md) | [29.0](/filings/0001326190-25-000040.md) | [32.8](/filings/0001326190-25-000064.md) | [55.0](/filings/0001326190-26-000052.md) | [51.6](/filings/0001326190-26-000040.md) | [53.0](/filings/0001326190-26-000052.md) |
| Long-term debt | $m | [4.3](/filings/0001326190-23-000047.md) | not reported | not reported | not reported | not reported | not reported | not reported | [14.3](/filings/0001326190-25-000040.md) | [14.4](/filings/0001326190-25-000064.md) | [34.3](/filings/0001326190-26-000052.md) | [34.5](/filings/0001326190-26-000040.md) | [34.7](/filings/0001326190-26-000052.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [150](/filings/0001326190-24-000050.md) | [194](/filings/0001326190-26-000018.md) | [173](/filings/0001326190-25-000064.md) | [153](/filings/0001326190-25-000064.md) | [133](/filings/0001326190-25-000064.md) | [124](/filings/0001326190-26-000052.md) | [142](/filings/0001326190-26-000052.md) | [161](/filings/0001326190-26-000052.md) | [186](/filings/0001326190-25-000064.md) | [225](/filings/0001326190-26-000052.md) | [284](/filings/0001326190-26-000052.md) | [474](/filings/0001326190-26-000052.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(20.5) d](/filings/0001326190-24-000050.md) | [(16.5) d](/filings/0001326190-25-000015.md) | [(16.4)](/filings/0001326190-25-000034.md) | [(18.1) d](/filings/0001326190-25-000040.md) | [(27.1) d](/filings/0001326190-25-000064.md) | [(18.3) d](/filings/0001326190-26-000018.md) | [(16.8)](/filings/0001326190-26-000040.md) | [(19.4) d](/filings/0001326190-26-000052.md) | [(11.9) d](/filings/0001326190-25-000064.md) | [(19.4) d](/filings/0001326190-26-000018.md) | [(20.9)](/filings/0001326190-26-000040.md) | [(24.2) d](/filings/0001326190-26-000052.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001326190-24-000050.md) | [0.0 d](/filings/0001326190-25-000015.md) | not reported | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001326190-25-000064.md) | [0.0 d](/filings/0001326190-26-000018.md) | [0.0](/filings/0001326190-26-000040.md) | [0.0 d](/filings/0001326190-26-000052.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [49.3](/filings/0001326190-23-000047.md) | [50.1](/filings/0001326190-24-000019.md) | [50.7](/filings/0001326190-24-000030.md) | [53.6](/filings/0001326190-24-000050.md) | [70.8](/filings/0001326190-25-000034.md) | [70.9](/filings/0001326190-25-000040.md) | [71.1](/filings/0001326190-25-000064.md) | [75.5](/filings/0001326190-26-000040.md) | [81.5](/filings/0001326190-26-000052.md) | [89.4](/filings/0001326190-25-000064.md) | [124](/filings/0001326190-26-000040.md) | [185](/filings/0001326190-26-000052.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 194,517,701 at 2026-08-07, from the cover of the [10-Q filed 2026-08-12](/filings/0001326190-26-000052.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:37 ET. No prices; not investment advice.